stopped tirzepatide Lilly demands doctors stop selling copycat weight-loss drugs TrimRX What is the Tirzepatide Starting

Adverse Reactions (2% and Greater Than Placebo) in WEGOVY-treated Adults with Obesity or Overweight for Weight Reduction In a CV outcomes trial, 8,803 patients were exposed to WEGOVY for a median of 37.3 months and 8,801 patients were exposed to placebo for a median of 38.6 months [see Clinical Studies (14.1)]

Rapid weight loss , a common effect of GLP-1 agonists, is a well-established risk factor for gallstone formation

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus and chronic weight management

This article explores the causes, management strategies, and when professional review is necessary for patients experiencing dizziness whilst taking Ozempic